AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study results with masitinib in severe asthma to be delivered as a late breaking oral presentation - Seite 4
For additional information, please contact:
AB Science
Financial Communication & Media Relations
investors@ab-science.com
Lesen Sie auch
Attachment
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte